1 | randomised | 35,269 |
2 | randomized-controlled | 431 |
3 | cluster-randomised | 309 |
4 | randomised-controlled | 85 |
5 | non-placebo | 11 |
6 | nicvax | 7 |
7 | thermostatically | 6 |
8 | conclusion.randomised | 3 |
9 | hikari | 3 |
10 | j-rapid | 3 |
11 | not-placebo | 3 |
12 | randomised/quasi-randomised | 3 |
13 | site-randomized | 3 |
14 | -randomized | 2 |
15 | asthma-defined | 2 |
16 | coin-flip | 2 |
17 | design-randomized | 2 |
18 | efficacy-based | 2 |
19 | fda-registered | 2 |
20 | i-randomized | 2 |
21 | ls-ocs | 2 |
22 | noac-investigating | 2 |
23 | nonprospective | 2 |
24 | placebo-randomised | 2 |
25 | randomizd | 2 |
26 | regular-administration | 2 |
27 | small-randomized | 2 |
28 | worksite-randomized | 2 |
29 | ~bullet~randomised | 2 |
30 | 10,025 | 1 |
31 | 2,462 | 1 |
32 | 30-centre | 1 |
33 | 5-major | 1 |
34 | 99/01 | 1 |
35 | antidepressants-beyond | 1 |
36 | arctic-monitoring | 1 |
37 | aspects.two | 1 |
38 | barostatically | 1 |
39 | blankly | 1 |
40 | bmnpv-mir-3-mediated | 1 |
41 | care.six | 1 |
42 | childrenin | 1 |
43 | cluster-randomised/quasi-randomised | 1 |
44 | color-congruent | 1 |
45 | discrediting | 1 |
46 | double-blind-design | 1 |
47 | double-mimic | 1 |
48 | double-sham | 1 |
49 | evidence.seven | 1 |
50 | group-parallel | 1 |
51 | head-injury | 1 |
52 | knowledge-randomized | 1 |
53 | long-term-randomized | 1 |
54 | male.five | 1 |
55 | mmx-plc-hcl | 1 |
56 | months.three | 1 |
57 | morphine-placebo | 1 |
58 | myoelectrically | 1 |
59 | non-randomisedrandomised | 1 |
60 | novartis-sponsored | 1 |
61 | office/clinically | 1 |
62 | ofrandomised | 1 |
63 | once-used | 1 |
64 | parallel-randomised | 1 |
65 | participants.four | 1 |
66 | patient-randomized | 1 |
67 | patients-preference | 1 |
68 | person-randomized | 1 |
69 | physician-randomized | 1 |
70 | placebo/inactive | 1 |
71 | poct- | 1 |
72 | post-randomised | 1 |
73 | priority.further | 1 |
74 | progesterone-impregnated | 1 |
75 | quasi-randomized/randomized | 1 |
76 | randomized/quasi-randomized | 1 |
77 | randomy | 1 |
78 | regimenssix | 1 |
79 | stimuli-response | 1 |
80 | studies-randomized | 1 |
81 | study/randomized | 1 |
82 | tamoxifen-placebo | 1 |
83 | trials.six | 1 |
84 | trials.three | 1 |
85 | trials.twenty-two | 1 |
86 | trials/clinical | 1 |
87 | two-person-30-day | 1 |
88 | untruncated | 1 |
89 | urn-randomized | 1 |
90 | waikato-tainui.this | 1 |
91 | zed | 1 |
1 | -randomized | 2 |
2 | 10,025 | 1 |
3 | 2,462 | 1 |
4 | 30-centre | 1 |
5 | 5-major | 1 |
6 | 99/01 | 1 |
7 | antidepressants-beyond | 1 |
8 | arctic-monitoring | 1 |
9 | aspects.two | 1 |
10 | asthma-defined | 2 |
11 | barostatically | 1 |
12 | blankly | 1 |
13 | bmnpv-mir-3-mediated | 1 |
14 | care.six | 1 |
15 | childrenin | 1 |
16 | cluster-randomised | 309 |
17 | cluster-randomised/quasi-randomised | 1 |
18 | coin-flip | 2 |
19 | color-congruent | 1 |
20 | conclusion.randomised | 3 |
21 | design-randomized | 2 |
22 | discrediting | 1 |
23 | double-blind-design | 1 |
24 | double-mimic | 1 |
25 | double-sham | 1 |
26 | efficacy-based | 2 |
27 | evidence.seven | 1 |
28 | fda-registered | 2 |
29 | group-parallel | 1 |
30 | head-injury | 1 |
31 | hikari | 3 |
32 | i-randomized | 2 |
33 | j-rapid | 3 |
34 | knowledge-randomized | 1 |
35 | long-term-randomized | 1 |
36 | ls-ocs | 2 |
37 | male.five | 1 |
38 | mmx-plc-hcl | 1 |
39 | months.three | 1 |
40 | morphine-placebo | 1 |
41 | myoelectrically | 1 |
42 | nicvax | 7 |
43 | noac-investigating | 2 |
44 | non-placebo | 11 |
45 | non-randomisedrandomised | 1 |
46 | nonprospective | 2 |
47 | not-placebo | 3 |
48 | novartis-sponsored | 1 |
49 | office/clinically | 1 |
50 | ofrandomised | 1 |
51 | once-used | 1 |
52 | parallel-randomised | 1 |
53 | participants.four | 1 |
54 | patient-randomized | 1 |
55 | patients-preference | 1 |
56 | person-randomized | 1 |
57 | physician-randomized | 1 |
58 | placebo-randomised | 2 |
59 | placebo/inactive | 1 |
60 | poct- | 1 |
61 | post-randomised | 1 |
62 | priority.further | 1 |
63 | progesterone-impregnated | 1 |
64 | quasi-randomized/randomized | 1 |
65 | randomised | 35,269 |
66 | randomised-controlled | 85 |
67 | randomised/quasi-randomised | 3 |
68 | randomizd | 2 |
69 | randomized-controlled | 431 |
70 | randomized/quasi-randomized | 1 |
71 | randomy | 1 |
72 | regimenssix | 1 |
73 | regular-administration | 2 |
74 | site-randomized | 3 |
75 | small-randomized | 2 |
76 | stimuli-response | 1 |
77 | studies-randomized | 1 |
78 | study/randomized | 1 |
79 | tamoxifen-placebo | 1 |
80 | thermostatically | 6 |
81 | trials.six | 1 |
82 | trials.three | 1 |
83 | trials.twenty-two | 1 |
84 | trials/clinical | 1 |
85 | two-person-30-day | 1 |
86 | untruncated | 1 |
87 | urn-randomized | 1 |
88 | waikato-tainui.this | 1 |
89 | worksite-randomized | 2 |
90 | zed | 1 |
91 | ~bullet~randomised | 2 |
1 | poct- | 1 |
2 | 99/01 | 1 |
3 | 2,462 | 1 |
4 | 10,025 | 1 |
5 | double-mimic | 1 |
6 | randomised-controlled | 85 |
7 | randomized-controlled | 431 |
8 | asthma-defined | 2 |
9 | fda-registered | 2 |
10 | novartis-sponsored | 1 |
11 | efficacy-based | 2 |
12 | randomised | 35,269 |
13 | randomised/quasi-randomised | 3 |
14 | cluster-randomised/quasi-randomised | 1 |
15 | parallel-randomised | 1 |
16 | placebo-randomised | 2 |
17 | cluster-randomised | 309 |
18 | post-randomised | 1 |
19 | conclusion.randomised | 3 |
20 | non-randomisedrandomised | 1 |
21 | ofrandomised | 1 |
22 | ~bullet~randomised | 2 |
23 | once-used | 1 |
24 | untruncated | 1 |
25 | bmnpv-mir-3-mediated | 1 |
26 | progesterone-impregnated | 1 |
27 | zed | 1 |
28 | -randomized | 2 |
29 | knowledge-randomized | 1 |
30 | site-randomized | 3 |
31 | worksite-randomized | 2 |
32 | i-randomized | 2 |
33 | randomized/quasi-randomized | 1 |
34 | small-randomized | 2 |
35 | long-term-randomized | 1 |
36 | physician-randomized | 1 |
37 | design-randomized | 2 |
38 | person-randomized | 1 |
39 | urn-randomized | 1 |
40 | studies-randomized | 1 |
41 | patient-randomized | 1 |
42 | quasi-randomized/randomized | 1 |
43 | study/randomized | 1 |
44 | j-rapid | 3 |
45 | antidepressants-beyond | 1 |
46 | randomizd | 2 |
47 | patients-preference | 1 |
48 | months.three | 1 |
49 | trials.three | 1 |
50 | 30-centre | 1 |
51 | stimuli-response | 1 |
52 | male.five | 1 |
53 | placebo/inactive | 1 |
54 | nonprospective | 2 |
55 | arctic-monitoring | 1 |
56 | noac-investigating | 2 |
57 | discrediting | 1 |
58 | hikari | 3 |
59 | trials/clinical | 1 |
60 | mmx-plc-hcl | 1 |
61 | group-parallel | 1 |
62 | double-sham | 1 |
63 | evidence.seven | 1 |
64 | double-blind-design | 1 |
65 | childrenin | 1 |
66 | regular-administration | 2 |
67 | morphine-placebo | 1 |
68 | tamoxifen-placebo | 1 |
69 | non-placebo | 11 |
70 | not-placebo | 3 |
71 | trials.twenty-two | 1 |
72 | aspects.two | 1 |
73 | coin-flip | 2 |
74 | priority.further | 1 |
75 | 5-major | 1 |
76 | participants.four | 1 |
77 | ls-ocs | 2 |
78 | waikato-tainui.this | 1 |
79 | color-congruent | 1 |
80 | nicvax | 7 |
81 | care.six | 1 |
82 | trials.six | 1 |
83 | regimenssix | 1 |
84 | two-person-30-day | 1 |
85 | blankly | 1 |
86 | office/clinically | 1 |
87 | myoelectrically | 1 |
88 | thermostatically | 6 |
89 | barostatically | 1 |
90 | randomy | 1 |
91 | head-injury | 1 |